Suppr超能文献

高效自然杀伤细胞与转移性前列腺癌患者的良好预后相关。

Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.

作者信息

Pasero Christine, Gravis Gwenaëlle, Granjeaud Samuel, Guerin Mathilde, Thomassin-Piana Jeanne, Rocchi Palma, Salem Naji, Walz Jochen, Moretta Alessandro, Olive Daniel

机构信息

Centre de Recherche en Cancérologie de Marseille, Inserm, Marseille, France.

Institut Paoli-Calmettes, Marseille, France.

出版信息

Oncotarget. 2015 Jun 10;6(16):14360-73. doi: 10.18632/oncotarget.3965.

Abstract

Clinical outcome of patients with metastatic prostate cancer (mPC) at diagnosis is heterogeneous and unpredictable; thus alternative treatments such as immunotherapy are investigated. We retrospectively analyzed natural killer (NK) cells by flow cytometry in peripheral blood from 39 mPC patients, with 5 year-follow-up, and their correlation with time to castration resistance (TCR) and overall survival (OS). In parallel, NK functionality was carried out against prostate tumor cell lines, analyzed for the expression of NK cell ligands, to identify the receptors involved in PC recognition. NK cells from patients with longer TCR and OS displayed high expression of activating receptors and high cytotoxicity. The activating receptors NKp30 and NKp46 were the most obvious predictive markers of OS and TCR in a larger cohort of mPC patients (OS: p= 0.0018 and 0.0009; TCR: p= 0.007 and < 0.0001 respectively, log-rank test). Importantly, blocking experiments revealed that NKp46, along with NKG2D and DNAM-1 and, to a lesser extent NKp30, were involved in prostate tumor recognition by NK cells. These results identify NK cells as potential predictive biomarkers to stratify patients who are likely to have longer castration response, and pave the way to explore therapies aimed at enhancing NK cells in mPC patients.

摘要

转移性前列腺癌(mPC)患者诊断时的临床结局具有异质性且不可预测;因此,人们正在研究免疫疗法等替代治疗方法。我们对39例mPC患者外周血中的自然杀伤(NK)细胞进行了流式细胞术回顾性分析,并进行了5年随访,研究其与去势抵抗时间(TCR)和总生存期(OS)的相关性。同时,对前列腺肿瘤细胞系进行了NK功能检测,分析了NK细胞配体的表达,以确定参与前列腺癌识别的受体。TCR和OS较长的患者的NK细胞表现出激活受体的高表达和高细胞毒性。在更大的mPC患者队列中,激活受体NKp30和NKp46是OS和TCR最明显的预测标志物(OS:p = 0.0018和0.0009;TCR:分别为p = 0.007和<0.0001,对数秩检验)。重要的是,阻断实验表明,NKp46与NKG2D和DNAM-1一起,以及在较小程度上的NKp30,参与了NK细胞对前列腺肿瘤的识别。这些结果表明NK细胞是潜在的预测生物标志物,可用于对可能有更长去势反应的患者进行分层,并为探索旨在增强mPC患者NK细胞的治疗方法铺平了道路。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验